Diella S. Babu

Diella S. Babu

Auto-generated profile, based on publicly available information

Diella S. Babu

Department of Radiology, Houston Methodist Research Institute, Houston, Texas

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 June 2026 in Cancer Immunology Research
Verified
Journal Article
Closed access
IMIrene M. Min
Irene M. Min
YYYanping Yang
Yanping Yang
DSDessislava Stefanova
Dessislava Stefanova
YVYogindra Vedvyas
Yogindra Vedvyas
DBDiella S. Babu
Diella S. Babu
MJMoonsoo Jin
Moonsoo Jin
Engineered T-cell therapies, such as chimeric antigen receptor (CAR)– and T-cell receptor (TCR)–based approaches, have transformed outcomes in hematologic malignancies, yet their efficacy in solid tumors remains limited by tumor antigen escape, immunosuppressive microenvironments, and insufficient activation of CAR or TCR signaling. To overcome these barriers, we developed an intercellular adhesion molecule 1 (ICAM1)–specific chimeric costimulatory receptor (ICCR) engineered for expression in T cells to augment their activation. ICAM1 is broadly expressed across solid tumors and is further upregulated by IFNγ released during early T-cell engagement, creating a feed-forward loop that reinforces tumor recognition. ICCR engagement with ICAM1 triggered NF-κB signaling independently of TCR–peptide (p)/MHC engagement; however, full T-cell activation and cytotoxic function remained dependent on intact TCR signaling. In primary T cells, ICCR increased proliferation, cytokine production, and cytotoxicity, resulting in improved tumor control in two anaplastic thyroid cancer xenograft models treated with allogeneic or autologous ICCR-T cells. Mechanistically, ICCR strengthened tumor cell engagement, promoted selection and expansion of tumor-specific TCR clonotypes, and amplified downstream signaling pathways. These findings identify ICCR as a strategy that leverages an immune synapse–mimetic mechanism to enhance the function of low-activity tumor-specific TCRs and improve T-cell responses in solid tumor microenvironments.

2 July 2026
Verified
Other
Open access
IMIrene M. Min
Irene M. Min
YYYanping Yang
Yanping Yang
DSDessislava Stefanova
Dessislava Stefanova
YVYogindra Vedvyas
Yogindra Vedvyas
DBDiella S. Babu
Diella S. Babu
MJMoonsoo Jin
Moonsoo Jin
Conjugate analysis of engineered T cells and IFNγ-prestimulated A375-MA2 cells

2 July 2026
Verified
Other
Open access
IMIrene M. Min
Irene M. Min
YYYanping Yang
Yanping Yang
DSDessislava Stefanova
Dessislava Stefanova
YVYogindra Vedvyas
Yogindra Vedvyas
DBDiella S. Babu
Diella S. Babu
MJMoonsoo Jin
Moonsoo Jin
Phenotypes of RM-ATC and donor-matched primary T cells

2 July 2026
Verified
Other
Open access
IMIrene M. Min
Irene M. Min
YYYanping Yang
Yanping Yang
DSDessislava Stefanova
Dessislava Stefanova
YVYogindra Vedvyas
Yogindra Vedvyas
DBDiella S. Babu
Diella S. Babu
MJMoonsoo Jin
Moonsoo Jin
Phenotypic analysis of engineered T cells

2 July 2026
Verified
Other
Open access
IMIrene M. Min
Irene M. Min
YYYanping Yang
Yanping Yang
DSDessislava Stefanova
Dessislava Stefanova
YVYogindra Vedvyas
Yogindra Vedvyas
DBDiella S. Babu
Diella S. Babu
MJMoonsoo Jin
Moonsoo Jin
TCRa depletion in ICCR-T cells